Antidepressant utilization in primary care in a Spanish region -: Impact of generic and reference-based pricing policy (2000-2004)

• Tipo: Artigo em Revista Científica Internacional
• Data: 2007

Autores

Ubeda, A (Autor) Outra; Cardo, E (Autor) Outra; Sellés, N (Autor) Outra; Broseta, R (Autor) Outra; Trillo, JL (Autor) Outra; Fernández Llimós, F (Autor) Outra

Revista

Título: Social Psychiatry and Psychiatric Epidemiology

Vol. 42

Páginas: 181-188

ISSN: 0933-7954

Editora: Springer Nature

Indexação

ISI Web of Knowledge - 17 Citações

Scopus - 17 Citações

Outras Informações

ID Authenticus: P-00F-T28

DOI: 10.1007/s00127-006-0149-9

Abstract (EN): Objective: To describe the evolution of antidepressant use in primary care in the Valencian region (Spain) from 2000 to 2004 and to analyze the effects of reference-based price and generic drugs introduction on drug utilization and cost saving. Methods: Retrospective observational study in primary care using sales data collected from antidepressant group (N06A), corresponding to the period 2000-2004. Defined daily dose (DDD)/1000 inhabitants per day were obtained as consumption data. Cost and cost/DDD rate evolution was related to reference price system implantation. Results: Antidepressant utilization progressively increased by 44.0% from 30.3 DDDs/1000 per day in 2000 to 43.5% in 2004. Selective serotonin reuptake inhibitors (SSRIs) comprised 77% of the total consumption where paroxetine, sertraline and fluoxetine were the most used drugs in 2004. The proportion of relative use and cost of fluoxetine declined after a reference price and the introduction of generic competitors were put into effect in 1999; cost/DDD was reduced by 1.8. Third-generation antidepressants showed a fast rising rate i.e. venlafaxine utilization multiplied by 2.2; this drug with the higher cost/DDD was not subjected to the reference price system. Reduction in citalopram utilization was related to a replacement by its recently marketed enantiomer escitalopram. Conclusions: In 2004, reference price policy and the implementation of generic drugs reduced the antidepressant cost by DDD. However, antidepressant expenditure increased since 2000 due to a continued growth in consumption (SSRIs and novel agents) and a displacement of prescriptions to drugs that were not included in the reference price policy. © Steinkopff Verlag Darmstadt 2007.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 8